FDA to Watson on 24-week Trelstar: Ummm, not yet. Oh, and to Bayer and J&J for Xarelto: Ummmm, not yet. Bayer's Yaz and blood clots - the legal wrangling continues. Solvay selling out on pharma, …
Today’s Top Three in Pharma 060409
OK, so it's a "baker's three" (8) today. Makes up for yesterday's zero...! Patent-holder urges FDA to NOT approve prasugrel (from Lilly/Daiichi Sankyo). Novartis getting cold feet at the Alcon …
Today’s Top Three in Pharma 040209
Solvay shopping its drug business. Belgian conglomerate Solvay is eying an exit of the drug business with a sale of its pharmaceutical division that could be worth upwards of €5 billion, or $6.6 …
Today’s Top Three in Pharma 032009
FDA panel recommends approval of J&J/Bayer anti-clotting drug - Government health advisers said Thursday the benefits of an experimental anticlotting drug from Johnson & Johnson outweigh its …
Pharma News this week
Sanofi-Aventis suspends sale of Acomplia in Europe. Acomplia, an obesity drug that once looked like it would be a blockbuster for Sanofi-Aventis, is being pulled off the market in Europe. The EMEA, …
Pharma News 9_12
King begins hostile takeover proceedings with Alpharma - Brain Markison, King’s ceo, is disappointed that Dean Mitchell, Alpharma’s ceo, hasn’t responded to his initial offer $1.4 billion offer, which …